Several companies shared new trial data at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco, US. 

Once-yearly lenacapavir for HIV prevention

Gilead Sciences presented the first data from its ongoing Phase I study investigating two once-yearly formulations of lenacapavir, an injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP). 

The Phase I study data showed that the two different formulations of once-yearly lenacapavir administered via intramuscular injection achieved and maintained plasma concentrations exceeding those associated with HIV prevention efficacy observed in the Phase III PURPOSE 1 trial and PURPOSE 2 trial.  

The previously reported PURPOSE 1 and PURPOSE 2 data showed that twice-yearly subcutaneous lenacapavir demonstrated superiority at reducing HIV infections when compared to background HIV incidence (bHIV) and once-daily oral Truvada. 

“Gilead is continuing to innovate in our work to develop additional person-centred long-acting injectable and oral options to help people find an HIV prevention choice that is right for them,” said Jared Baeten, Senior Vice President, Virology Therapeutic Area Head, Gilead Sciences. “Once-yearly lenacapavir, if approved, could become an important new HIV prevention option that could help address PrEP adherence and persistence challenges for individuals who need or want PrEP around the world.” 

Biktarvy in people with HIV and HBV coinfection

Gilead also shared results from ALLIANCE, an ongoing Phase III study evaluating Biktarvy versus dolutegravir 50mg (DTG) + emtricitabine 200mg/tenofovir disoproxil fumarate 300mg, F/TDF, DTG+F/TDF, in adults with HIV-1/HBV co-infection initiating treatment.  

The ALLIANCE trial is the first randomised clinical trial of TAF- vs TDF-based regimens in treatment naïve adults with HIV/HBV coinfection. 

Week 48 outcomes from the open-label extension phase show that Biktarvy maintained high rates of HIV-1 (95.4%) and HBV (86.6%) virologic suppression, defined as HIV RNA <50 copies/mL and HBV DNA <29 IU/mL, respectively, in participants following a switch to Biktarvy after 96 weeks of treatment with DTG+ F/TDF. 

Lenacapavir and broadly neutralising antibodies (bNAbs)

In a third presentation, Gilead shared the primary results of a Phase II study evaluating the investigational combination of lenacapavir (LEN) with bNAbs (teropavimab [GS-5423, TAB] and zinlirvimab, or LEN+TAB+ZAB (LTZ). 

Efficacy and safety results were evaluated when virologically suppressed adults switched to LTZ every six months versus staying on stable baseline oral antiretroviral regimen.  

The study met its primary endpoint, which is the proportion of participants with HIV-1 RNA ≥ 50 copies/mL at Week 26 as determined by the US FDA-defined snapshot algorithm. 

The Week 26 data demonstrated the high efficacy of the LTZ regimen, with 96% of participants who received LTZ and 96% who received SBR remained virologically suppressed.  

CD4 cell counts also increased from baseline to week 26 in both groups, with a mean change of +23/μL (n=143) with LTZ and +69/μL (n=203) with SBR.  

HIV cure clinical trial

Finally, Gilead presented results from the first HIV cure trial to be conducted in South Africa, which has demonstrated that complex cure studies can be successfully conducted, alongside community, in resource-limited settings where great unmet need exists. 

The Phase IIa GS-US-382-5445 trial enrolled 20 South African cisgender women from the Females Rising through Education, Support, and Health (FRESH) cohort who had received antiretroviral therapy (ART) soon after acquiring HIV and were virologically suppressed for at least 12 months. 

Participants received up to 10 oral doses of Gilead’s investigational TLR7 agonist, vesatolimod, every two weeks starting on Day 0, plus IV infusions of broadly neutralising antibodies (bNAbs) VRC07-523LS and CAP256V2LS, provided by the National Institutes of Health (NIH), on Day 7.  

Participants began an analytical treatment interruption (ATI) on Day 35 and remained off ART until Week 48, or until they met restart criteria. Participants who reached Week 48 without meeting ART restart criteria had the option of remaining off ART through the end of study follow-up at Week 60. 

While the data suggest that the trial regimen alone is not sufficient as an HIV cure regimen, the mechanistic learnings will inform the development of future cure approaches. 

Broadly neutralising antibody N6LS 

ViiV Healthcare announced positive findings from the company’s EMBRACE Phase IIb study. 

The study found that N6LS (VH3810109 or VH109), given every four months in combination with monthly cabotegravir long-acting (CAB LA), successfully kept viral levels suppressed in adults living with HIV who were already stable on treatment. It was also well tolerated by participants.   

Kimberly Smith, Head of Research & Development at ViiV Healthcare, said: “As leaders in long-acting injectable innovation, we are building on the positive patient and physician experience we have with Cabenuva and pioneering the next generation of long-acting treatment options.  

“The EMBRACE study demonstrated that VH109, a CD4-binding broadly neutralising antibody, administered every four months with cabotegravir, achieved high efficacy and was well tolerated through six months. We’re looking forward to continuing the development of VH109 as a component of our future ultra long-acting regimens.”   

Results from the EMBRACE study at the six-month primary endpoint showed that 96% of participants receiving VH109 60mg/kg intravenously (IV) and 88% receiving VH109 3000mg subcutaneously (SC) with rHuPH20 maintained HIV-1 RNA levels below 50 copies/mL, compared to 96% in the standard-of-care group. 

Oral antiviral prevents Covid-19

Shionogi & Co shared new data from its Phase III study, Stopping Covid-19 pRogression with early Protease InhibitOr treatment – Post-Exposure Prophylaxis (SCORPIO-PEP) assessing ensitrelvir as oral post-exposure prophylaxis. 

The study met both the primary endpoint and the key secondary endpoint. Of the study participants treated with ensitrelvir, 2.9% developed symptomatic Covid-19 compared to 9.0% of participants on placebo at Day 10, the primary endpoint, representing a 67% relative risk reduction. 

“SARS-CoV-2 continues to circulate and there are still thousands of hospitalisations and hundreds of Covid-19 deaths each week,” said Simon Portsmouth, Senior Vice President, Head of Clinical Development. “If we can reduce the risk of infection among individuals who are exposed to SARS-CoV-2, this fulfils an important unmet medical need. Oral antivirals have changed the way we treat and prevent other infectious diseases, including influenza and HIV, and there is an opportunity to do the same with Covid-19.”

Diana Spencer, Senior Digital Content Editor, DDW